Corbus presents Phase 1b CANYON-1 data for CRB-913 at ObesityWeek 2026Nov 16Clinical readoutCorbus Pharmaceuticals Holdings, Inc.
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Corbus Pharmaceuticals files $127.5 million at-the-market stock offeringAug 7FinancingCorbus Pharmaceuticals Holdings, Inc.
Corbus reports Q2 2026 results, clears FDA hurdle for CRB-701 trialAug 6Quarterly updateCorbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals names Leonardo Viana Nicacio as chief medical officerJul 6PeopleCorbus Pharmaceuticals Holdings, Inc.